Results 41 to 50 of about 1,304,365 (227)

Chaotic dephasing in a double-slit scattering experiment

open access: yes, 2010
We design a computational experiment in which a quantum particle tunnels into a billiard of variable shape and scatters out of it through a double-slit opening on the billiard's base.
Baltes H. P.   +2 more
core   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

open access: yesMolecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken   +3 more
wiley   +1 more source

TCEC Cup 3 [PDF]

open access: yes, 2019
This is a report of the 'TCEC Cup 3' computational experiment, the 3rd TCEC knockout event and the second major part of TCEC’s 15th season. It featured the best 32 engines of the ‘TCEC 15’ league event and the games were held at Blitz tempo.
Haworth   +4 more
core   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

open access: yesMolecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice   +16 more
wiley   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Efficient numerical solution of the time fractional diffusion equation by mapping from its Brownian counterpart

open access: yes, 2015
The solution of a Caputo time fractional diffusion equation of order ...
Philippa, Bronson   +3 more
core   +1 more source

Express: a web-based technology to support human and computational experimentation [PDF]

open access: yes, 2003
Experimental cognitive psychology has been greatly assisted by the development of general computer-based experiment presentation packages. Typically, however, such packages provide little support for running participants on different computers.
Cooper, Richard P., Yule, P.
core   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

open access: yesMolecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix   +13 more
wiley   +1 more source

Understanding Parton Distributions from Lattice QCD: Present Limitations and Future Promise

open access: yes, 2002
This talk will explain how ground state matrix elements specifying moments of quark density and spin distributions in the nucleon have been calculated in full QCD, show how physical extrapolation to the chiral limit including the physics of the pion ...
Negele, J. W.
core   +2 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy